Yıl 2020, Cilt 6 , Sayı 3, Sayfalar 268 - 269 2020-05-04

May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome?

Arzu EKİCİ [1]


No abstract available.
PFAPA syndrome, periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis
  • 1. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010;99:178-84.
  • 2. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 2013;135:15.
  • 3. Stojanov S, Hoffmann F, Kéry A, Renner ED, Hartl D, Lohse P, et al. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 2006;17:90-7.
  • 4. Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009;4:e6453.
  • 5. Taniguchi K, Ono N, Sakai T, Ichiyama Y, Uemichi K. Response to cimetidine in a 1-year-old child with PFAPA syndrome. Turk J Pediatr 2016;58:687-9.
Birincil Dil en
Konular İmmünoloji
Bölüm Letter to the Editor
Yazarlar

Orcid: 0000-0002-0813-7189
Yazar: Arzu EKİCİ (Sorumlu Yazar)
Kurum: Department of Pediatric Neurology, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
Ülke: Turkey


Tarihler

Yayımlanma Tarihi : 4 Mayıs 2020

EndNote %0 The European Research Journal May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? %A Arzu EKİCİ %T May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? %D 2020 %J The European Research Journal %P -2149-3189 %V 6 %N 3 %R doi: 10.18621/eurj.666806 %U 10.18621/eurj.666806